se presentan dos casos de hepatitis viral en los cuales la terapia convencional no fue efectiva .
ambos fueron tratados posteriormente segn protocolos de uso de medicamentos homeopticos , como se describe a continuacin .
ambos pacientes registraron una remisin sostenida durante 2 aos , luego de consumir medicamentos naturales ultradiluidos y de que se descontinuaran sus correspondientes tratamientos convencionales .
el protocolo de tratamiento incluy como medicamentos principales chelidonium majus ( celidonia mayor ) 6x y thuja ( tuya ) 30c .
se confirmaron casos de desarrollo de anti - cuerpos estndares contra la hepatitis y mediciones de carga viral .
se realiz un seguimiento de los pacientes durante ms de 2 aos con mediciones de carga viral , enzimas hepticas y otros marcadores biolgicos relevantes de enfermedades hepticas .
ambos pacientes viven y se desenvuelven normalmente en sus hogares , luego de transcurridos ms de 2 aos desde el inicio del tratamiento .
discusin : analizamos la informacin relacionada con los medicamentos principales empleados en estos casos y descubrimos que tienen efectos teraputicos conocidos y demostrados que sugeran mecanismos de accin convincentes aplicables a estos casos .
los ensayos clnicos de este protocolo de tratamiento homeoptico se deben llevar a cabo para analizar los efectos teraputicos potenciales de este tipo de medicamentos para el tratamiento de la hepatitis viral .
on a routine health maintenance visit in 1994 , a 37-year - old woman was found to have elevated liver enzymes .
her first liver biopsy in january 1998 showed grade 1 ( of 4 ) inflammation and stage 1 to 2 ( of 4 ) delicate bridging fibrosis .
subsequent hepatitis c antibody testing revealed chronic hepatitis c. genotyping of the virus in 1998 revealed type 1b with a viral count of 33 000 000 iu / ml .
she enrolled in a clinical trial of pegylated inter - feron ( peg - inf ) subcutaneously 1.5 [ .proportional]g / kg once a week for 4 weeks followed by peg - inf 0.5 [ .proportional]g / kg once a week for 44 weeks along with ribavirin 1000 mg orally daily , which was reduced to 600 mg daily due to anemia at treatment week 30 .
her virologic response using polymerase chain reaction ( pcr)based assay for hepatitis c virus rna showed a temporary response .
posttreatment liver biopsy performed 6 months after completing treatment ( in july 2000 ) was scored as grade 3 of 4 inflammation and stage 1 of 4 fibrosis with piecemeal necrosis consistent with relapse .
a biopsy conducted in december 2003 showed inflammation grade 3 and fibrosis stage 3 of 4 .
in april 2004 , she started a second course of peg - inf with ribavirin after undergoing whole - body hyperthermia .
after 6 months , she was found to have no response to the interferon , and the drugs were discontinued .
a biopsy in november 2005 showed stage 3 of 4 fibrosis and moderate ( 3 of 4 ) portal inflammation .
viral count in july 2006 was 14 250 000 iu / ml , and the patient was found to have persistent stage 3 of 4 fibrosis and grade 3 of 4 inflammation with bridging necrosis . in august 2006 ,
the following protocol was used : chelidonium 6x twice a day , thuja 30c twice a day , and kalium muriaticum 3x and ferrum phosphoricum 3x twice a day .
the 6x potency is the 6th decimal potency that is achieved by serial dilution and agitation of the mother tincture , or alcoholic extract , of the root of the plant chelidonium majus .
thuja 30c is likewise the 30th centesimal serial dilution and agitated product ; here , the alcoholic extract is from the fresh leaves and small twigs of the young thuja occidentalis plant .
the kali muriaticum 3x and ferrum phosphoricum 3x are triturations of the substances to the 3rd decimal potency .
the medicine was procured from reputable homeopathic drug manufacturers and manufactured as per the homeopathic pharmacopoeia of india .
chelidonium 6x and thuja 30c are our standard protocol for cases of chronic viral hepatitis .
chelidonium has a strong body of research supporting its use for liver disease , and thuja is effective in treating a wide variety of viral infections ( see discussion section ) .
the combination of kali muriaticum and ferrum phosphoricum is our standard protocol for treatment of anemia , which this patient experienced as a side effect of interferon / ribavirin therapy .
the patient adhered to this protocol for 2 years and was rebiopsied in the united states in december 2008 .
her inflammation was reduced to stage 1 of 4 , and her fibrosis had regressed to stage 01a of 4 .
as of june 2011 , she remained in remission and continued treatment with chelidonium 6x twice a day .
case 1 : chronic active hepatitis c homeopathic treatment initiated august 2006 ; as of june 2011 , patient remained in remission .
abbreviations : hcv , hepatitis c virus ; rna , ribonucleic acid ; pcr , polymerase chain reaction .
in late november 2007 , a 28-year - old male was admitted to the premier indian medical institution , the all india institute of medical science ( aiims ) in delhi , for a case of hepatitis b virus ( hbv)related chronic liver disease decompensated by acute hepatitis e virus ( hev ) infection .
his clinical history included a rapidly progressing jaundice followed by pedal edema , ascites , fever , and abdominal tenderness .
viral antibody testing revealed a positive australia antigen ( hepatitis b surface antigen ) , negative immunoglobulin m for hepatitis b core antigen , hbv dna 1300 copies / ml , and positive immunoglobulin m antibody for hev . at aiims , he was treated with intravenous glycyrrhizin ( 0.2% ) 60 ml daily for 6 weeks , and then the dose was reduced to 3 times a week .
additionally , he received daily diuretic treatment with spironolactone / furosemide ( lasilactone , sanofi - aventis ) 50 to 75 mg per day , 20% albumin 100 ml intravenously daily for the first 2 months of hospitalization , cefuroxime axetil ( ceftum , glaxosmithkline ) 500 mg twice a day for 4 weeks , and lamivudine - hbv 100 mg daily .
after 6 weeks of hospitalization and treatment at aiims , the patient 's serum bilirubin continued to be markedly elevated and alanine transaminase was continuously 75 times normal , indicating failure of conservative treatment .
they refused to have him placed on the transplant list , and he was discharged in january 2008 and returned to kolkata .
after repeated episodes of spontaneous bacterial peritonitis requiring multiple hospitalizations in kolkata , he developed right hepatic hydrothorax .
at this point , the patient sought treatment at pbhrf . on first presenting at pbhrf on august 22 , 2008 , he had severe ascites , dyspnea without exertion , abdominal pain , and 4 + pitting edema in the lower extremities .
treatment was initiated with the following protocol : chelidonium 6x 3 drops alternating 3 times a day with carduus marianus ( milk thistle ) mother tincture 10 drops , thuja 30c 2 pills once every evening , lycopodium clavatum 30c 3 drops 3 times a day , and belladonna 3c alternating with carduus marianus mother tincture every 10 minutes as needed for pain .
in addition to our first - line agent , chelidonium , we added carduus marianus , as it has a long history of use in traditional herbal medicine for support of liver problems .
lycopodium is our first - line agent for treatment of edema or fluid retention of any kind .
belladonna is one of our first - line agents for pain , particularly pain of visceral origin .
when the patient 's condition did not improve , on september 15 , 2008 , myrica ( bayberry ) mother tincture was added , alternating every 3 hours with chelidonium 6x , and carduus was discontinued . on september 27 , acetic acid 30c ,
another of our prime medicines for water retention and effusions , 3 drops 3 times a day replaced the lycopodium for management of the ascites .
by december 13 , 2008 , the patient 's pleural effusion was clearing , ascites had decreased substantially , and urine output improved significantly .
clinic notes from january 7 , 2009 , reported worsening of the pleural effusion and ascites , and treatment exclusively by pbhrf continued with the expectation that improvement was likely to recur . by march 2009 ,
the patient was reporting a sustained improvement in symptoms , and the pleural effusion and ascites had almost completely subsided .
on june 3 , 2009 , the hbv dna count was 5.82 copies , and the patient was feeling well .
blood work done on may 9 , 2009 , revealed liver function tests generally near the normal range , as indicated in table 2 .
table 2 also shows the continued improvement in liver function tests when retested in december 2009 . as of june 2011
, the patient continued to feel well , having been in remission for 2 years .
case 2 : hepatitis b virus and hepatitis e virus homeopathic treatment initiated august 2008 ; as of june 2011 , the patient remained in remission .
abbreviations : alk phos , alkaline phosphatase ; alt , alanine transaminase ; ast , aspartate transaminase ; ggt , gamma - glutamyl transferase ; inr , international normalized ratio ; tbili , total bilirubin .
the protocols used in these cases were developed based on the extensive experience of the physicians at pbhrf , which spans several generations , as well as the known actions of its specific component medicines .
chelidonium majus ( greater celandine ) is an herb with documented hepatotoxic properties in its undiluted tincture or herbal form , but it has also been shown to have hepatoprotective , antitumor , and immunostimulatory actions . 

thuja and its related species also have been reported to have antiviral and antimetastatic properties .
myrica , or bayberry , is a common herb that is high in tannins ; there is virtually no research documenting its effectiveness in treatment of liver disease , but standard homeopathic references all list jaundice as one of its principle indications . 

the conclusion of this rigorous review was that milk thistle could potentially affect alcoholic and/or hepatitis b or c virus liver diseases .
therefore , large - scale randomized clinical trials on milk thistle for alcoholic and/or hepatitis b or c liver diseases versus placebo are needed . 
 
the larger issue is how ultradilute , serially agitated preparations of these biologically active substances are able to exert therapeutic effects even when the dilutions exceed avogadro 's number , which is the case for the dilutions of 30c used in the banerji protocol for hepatitis . the preparations of chelidonium are diluted to a factor of 1/1 000 000 ; this explains the lack of toxicity observed in the normally hepatotoxic chelidonium when in its crude form but does not explain its effectiveness as a hepatoprotectant .
the emerging disciplines of complexity , nanoscience , and materials science offer some hypotheses on how these ultradilute medicines may still maintain biological activity .
one research team advocated the hypothesis based on available scientific evidence and logic that one major pathway of ultra - dilute homeopathic drugs could possibly be through regulation of expression of relevant genes . a recent study by frenkel et al provided solid support for this hypothesis .
the medicines used by pbhrf for treatment of breast cancer were tested in vitro at the university of texas md anderson cancer center , houston .
the remedies exerted preferential cytotoxic effects against 2 breast cancer cell lines , causing cell cycle delay / arrest and apoptosis .
the researchers demonstrated a clear biological activity of the tested natural products ( phytolacca , carcinosin , conium , and thuja ) when present at ultradiluted doses . despite the lack of a proven explanation for how these ultradilute medicines exert their effects
, there is significant laboratory evidence that highly dilute toxins can paradoxically protect the very tissues they harm in macrodoses .
there are several reports of liver damage reversal in mice with ultradilutions of arsenic trioxide after exposure to toxic doses of the same substance .
one randomized double - blind placebo - controlled human study documented favorable improvements in multiple markers of arsenic toxicity after 2 months of treatment with a serially agitated dilution ( 1:100 dilution 30 times ) of arsenic , or the 30th centesimal potency . a recent review of the in vitro research on serially diluted and agitated solutions concluded that even the studies with high methodological standards demonstrated an effect of these solutions . a number of articles have been published in medical journals denouncing categorically the use of homeopathic medicine , claiming that there is no evidence to support any further research into their therapeutic effects .
clearly , even in this very brief research review and in these case reports , there is enough to suggest that this is an area that should be further explored .
the era of nanomedicine is upon us and requires a fresh look at medicines that are ultradiluted .
a major advantage of treating disease with ultradilute solutions is that adverse effects are virtually eliminated .
the case reports in this article will , hopefully , inspire a fresh interest and further research in this fascinating and controversial area of therapeutics .
 abstractintroduction : two cases of viral hepatitis that had failed conventional therapy are presented . 
 both were subsequently treated with protocols using homeopathic medicines as detailed below . 
 both patients sustained remissions for 2 years after taking ultradilute natural medicines after their conventional treatment had been discontinued.methods:the treatment protocol included chelidonium majus 6x and thuja 30c as the main medicines . 
 other homeopathic medicines were used as detailed below . 
 cases were confirmed with standard hepatitis antibody and viral measurements . 
 patients were followed for more than 2 years with measurements of viral counts , liver enzymes , and other relevant biomarkers of liver disease.results:both patients are alive and functioning normally in their home environments more than 2 years after treatment initiation.discussion:we review the literature related to the chief medicines used in these cases and find that they have known and demonstrated therapeutic effects suggesting plausible mechanisms of action in these cases.conclusions:clinical trials of this homeopathic treatment protocol should be conducted to explore the therapeutic potential of these medicines for treatment of viral hepatitis . 
Introduccin:
Mtodos:
Resultados:
Conclusiones:
CASE 1
CASE 2
DISCUSSION